Frankfurt
05.06.26 | 15:25
3,380 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Inventiva S.A. - 6-K, Report of foreign issuer | 10 | SEC Filings | ||
| Di | INVENTIVA: Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris | 220 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), June 2, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| Di | INVENTIVA: Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout | 374 | GlobeNewswire (Europe) | Secured a new debt financing with funds and accounts managed by BlackRock and Claret Capital Partners, respectively for up to €130 million in committed tranches, subject to conditions, plus an additional... ► Artikel lesen | |
| Di | INVENTIVA: Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris | 452 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), June 2, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 27.05. | Inventiva S.A reports Q1 results | 2 | Seeking Alpha | ||
| INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
| 26.05. | INVENTIVA: Inventiva Reports 2026 First Quarter Financial Information | 1.501 | GlobeNewswire (Europe) | Cash and cash equivalents at €75.0 million, and €121.5 million in short-term deposits2
Daix (France), New York City (New York, United States), May 26, 2026 - Inventiva (Euronext Paris and NASDAQ:... ► Artikel lesen | |
| 22.05. | Inventiva S.A. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 21.05. | INVENTIVA: Inventiva to Present at 2026 Jefferies Global Healthcare Conference | 344 | GlobeNewswire (Europe) | Daix (France), New York (United States), May 21, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 13.05. | INVENTIVA: Inventiva to Present Abstracts at the EASL Congress 2026 | 421 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), May 13, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 01.05. | Inventiva appoints Axel-Sven Malkomes as Chief Financial Officer | 9 | PMLiVE | ||
| 22.04. | Inventiva announces CFO appointment | 2 | Seeking Alpha | ||
| 22.04. | Inventiva stärkt Führungsteam vor entscheidenden Studienergebnissen | 11 | Investing.com Deutsch | ||
| 22.04. | INVENTIVA: Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor | 594 | GlobeNewswire (Europe) | Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva's organizational build-out as it advances toward potential commercialization.Axel-Sven Malkomes... ► Artikel lesen | |
| 22.04. | Inventiva S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 08.04. | INVENTIVA: Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F | 633 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), April 8, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 08.04. | Inventiva S.A. - 20-F, Annual and transition report of foreign private issuers | 4 | SEC Filings | ||
| 07.04. | Piper Sandler reiterates Inventiva stock rating ahead of trial | 11 | Investing.com | ||
| 31.03. | MASH-Studie: Leerink bekräftigt positive Einschätzung für Inventiva | 11 | Investing.com Deutsch | ||
| 31.03. | Leerink reiterates Inventiva stock rating on MASH trial progress | 2 | Investing.com | ||
| 31.03. | Stifel cuts Inventiva stock price target on dilution concerns | 3 | Investing.com |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 2,900 | -1,16 % | Aurora Deepens its Impact for Veterans Across Canada | ||
| VERTEX PHARMACEUTICALS | 392,50 | +1,22 % | Vertex Pharmaceuticals Incorporated: Vertex Presents New Data on ALYFTREK at European Cystic Fibrosis Conference | - ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels... ► Artikel lesen | |
| CRONOS GROUP | 2,416 | +1,00 % | Cronos Group Inc.: Cronos Group Reports 2026 First Quarter Results | Net revenue in Q1 2026 increased by 40% year-over-year to $45.2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada1 Ninth consecutive quarter... ► Artikel lesen | |
| VIATRIS | 13,794 | +0,15 % | Dividendenbekanntmachungen (22.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,78 USD 0,6712 EUR ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0645 EUR ADVANCED ENERGY INDUSTRIES... ► Artikel lesen | |
| EYEPOINT | 10,200 | 0,00 % | EyePoint, Inc.: EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU, Building Confidence Ahead of Mid-2026 Topline Data | - LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after - - Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four previously... ► Artikel lesen | |
| BAUSCH HEALTH | 4,640 | 0,00 % | Bausch Health Companies Inc.: Bausch Health Announces 2026 Annual Meeting of Shareholder Results | LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 75,08 | -0,79 % | Is Edwards Lifesciences Stock Underperforming the Nasdaq? | ||
| ORGANIGRAM GLOBAL | 0,947 | +2,38 % | Organigram Global Inc.: Organigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit Facilities | Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram") and Sanity Group GmbH ("Sanity" or "Sanity Group") jointly announced the successful closing of Organigram's previously... ► Artikel lesen | |
| SNDL | 1,250 | +1,79 % | 1CM Inc.: 1CM Provides Update on Arrangement Agreement with SNDL | Toronto, Ontario--(Newsfile Corp. - May 27, 2026) - 1CM Inc. (CSE: EPIC) (OTCQB: MILFF) (FSE: IQ70) ("1CM") announces that it does not expect the proposed sale of its Ontario retail locations to... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 3,760 | +1,24 % | Quantum BioPharma Provides Corporate Update | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, June 01, 2026... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 0,935 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Heal Wellness QSR Announces the Grand Opening of Its Newest Location in Woodstock, Ontario | Toronto, Ontario--(Newsfile Corp. - June 5, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 9,526 | -0,87 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 ... | Real-world analysis of three years of closed claims data from Symphony Health focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgia Data... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,150 | +0,70 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q1 2026 Financial Results and Business Update | AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| CANTOURAGE GROUP | 6,340 | -1,86 % | EQS-DD: Cantourage Group SE: Philip Schetter, Annahme der Gewährung von 25.000 Aktienoptionen (Bezugsrechten auf Aktien der Cantourage Group SE; ISIN: DE000A3DSV01) im Rahmen des von der ... | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
05.06.2026 / 21:06... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 3,190 | -1,09 % | Lifeward Ltd.: Lifeward Successfully Closes on Strategic Partnership with Oramed | HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen |
INVENTIVA SA ADR gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,380 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVENTIVA SA ADR finden Sie auf Wallstreet Online.